This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Systemic Lupus Erythematosus
  • /
  • Efficacy and Safety of Efavaleukin Alfa in Subject...
Clinical trial

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Read time: 1 mins
Last updated:22nd Dec 2020
Status: Not yet recruiting
Identifier: NCT04680637
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus


The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active SLE.


Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
Estimated Study Start Date: May 25, 2021
Estimated Primary Completion Date: June 19, 2024
Estimated Study Completion Date: June 19, 2024

Arm:
- Placebo Comparator: Placebo + Standard of Care
- Experimental: Efavaleukin Alfa Dose Level One + Standard of Care
- Experimental: Efavaleukin Alfa Dose Level Two + Standard of Care
- Experimental: Efavaleukin Alfa Dose Level Three + Standard of Care

Category Value
Study type(s) Interventional
Expected enrolment 320
Actual Study start date 25 May 2021
Estimated Study Completion Date 19 June 2024

View full details